

**ICON Clinical
Research GmbH**

Heinrich-Hertz-Straße 26
63225 Langen, Germany

Tel +49 6103 904 0
Fax +49 6103 904 100

www.iconplc.com

BVMA member since 2001
Audits passed in 2001, 2003,
2006, 2009, 2012 and 2015



HISTORY AND MISSION

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. Today, ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries supporting clinical development from compound selection to Phase I-IV clinical studies. Currently, ICON operates from 77 locations in 38 countries and has approximately 11,700 employees. More information is at www.iconplc.com.



HIGHLIGHTS

ICON is a trusted development partner for the world's largest pharmaceutical companies.

90% of the world's top 20 drugs have been developed with ICON's help.

Operating under strategic partnership models is one of ICON's strengths and the company counts Pfizer, Bristol-Myers Squibb and Ely Lilly amongst its strategic partners.

SERVICES

- ▷ Phase I-IV Clinical Trial Design, Management and Review, Consulting
- ▷ Clinical Pharmacology
- ▷ Global Central and Bioanalytical Laboratory Services
- ▷ Clinical Pathology
- ▷ Biomarker Services, Pharmacodynamic/Pharmacokinetic Analysis
- ▷ Data Management
- ▷ Medical and Safety Services
- ▷ Biostatistics
- ▷ Interactive Technologies: IVR, IWR, ePRO
- ▷ Site and Patient Recruitment
- ▷ Medical Imaging
- ▷ Medical Writing
- ▷ Program Management
- ▷ Clinical Risk Management
- ▷ Strategic Resourcing & FSP
- ▷ Health Economics & Outcomes Research
- ▷ Pricing & Market Access
- ▷ Language Services
- ▷ Scientific Communications & Managed Markets
- ▷ Medical Device Trials

In addition ICON has a focus on adaptive trial design. For more than 15 years we have been involved in the development of the methodology for interim analyses and the planning and execution of adaptive clinical trials.

To date, ICON have planned and successfully conducted over 200 adaptive clinical trials across all phases. As a result of our well-established procedures and our extensive experience, we manage to provide interim reports to DMCs/DSMBs within a few working days after database lock.